Skip to main content
2024 Canadian Cardiovascular Congress Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Handout
Handout
Networking
Networking
On-Demand
On-Demand
Early Career Involvement
Early Career Involvement
Back
Session Evaluation

ACCREDITED SYMPOSIA

306 - REVOLUTIONIZING CARDIORENAL CARE: THE ROLE OF INCRETIN THERAPIES IN RISK REDUCTION

Saturday, October 26, 2024
12:30 PM – 1:30 PM PT
Room: 109-110
On-Demand
Recent advancements in incretin therapies have significantly expanded their role in clinical guidelines, particularly in managing cardiovascular and renal risks. These therapies are now recognized not only for their glycemic control benefits in type 2 diabetes but also for their profound impact on cardiorenal protection, prompting a shift in treatment paradigms.

This symposium will explore the evolving role of incretin therapies in cardio-kidney protection, emphasizing their relevance for cardiologists. Attendees will gain insights into key clinical trials, including SELECT, STEP-HFpEF, and FLOW, and understand the implications of these studies for current practice. The multidisciplinary panel of endocrinology and cardiology experts will discuss available incretin therapies and provide practical strategies for their integration into patient care. By the end of the symposium, participants will be better equipped to effectively apply these therapies to reduce cardio-kidney risks.

Learning Objectives:

At the end of this session participants will be able to:
  • discuss recent incretin cardio-kidney clinical trials and guidelines and the evolution of the pillars of cardio-kidney protection (medical expert, scholar)
  • differentiate the various incretin therapies that are currently available (medical expert, scholar)
  • apply practical strategies to implement the use of incretin therapies for cardio-kidney risk reduction (medical expert, health advocate)
Disclosure(s):
Akshay Jain, MD, FRCPC, FACE, CCD, ECNU, DABOM: Abbott: Consultant/Advisory Board (Ongoing), Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Amgen: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Astra Zeneca: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Bausch Healthcare: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Bayer: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Boehringer Ingelheim: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); CPD network: Speaker/Honoraria (Ongoing); Dexcom: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Diabetes Canada: Speaker/Honoraria (Ongoing); Eisai: Speaker/Honoraria (Ongoing); gsk: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); HLS Therapeutics: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Insulet: Consultant/Advisory Board (Ongoing); MDBriefcase: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); medtronic: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Moderna: Speaker/Honoraria (Ongoing); Novo Nordisk: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Partners in Progressive Medical Education: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Pfizer: Speaker/Honoraria (Ongoing); PocketPills: Consultant/Advisory Board (Ongoing); roche: Consultant/Advisory Board (Ongoing); Sandoz: Consultant/Advisory Board (Ongoing); sanofi aventis: Speaker/Honoraria (Ongoing); Takeda: Consultant/Advisory Board (Ongoing); Timed Right: Consultant/Advisory Board (Ongoing)
Abhinav Sharma, MD, FRCPC: AREA19: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); AstraZeneca: Speaker fees (Ongoing); Boehringer Ingelheim: Speaker fees (Ongoing); Janssen: Speaker fees (Ongoing); Novartis: Speaker fees (Ongoing); Novo Nordisk: Speaker fees (Ongoing); Roche Diagnostics: Speaker fees (Ongoing); Servier: Speaker fees (Ongoing)